Dr Reddy’s Laboratories Share Price Hit 1-Month Low Amidst Antitrust Allegations

Dr Reddy’s Laboratories (DRL), a global pharmaceutical company, has found itself entangled in a series of lawsuits filed between 2023 and 2024. These legal disputes revolve around allegations that the company, alongside others, delayed the market entry of generic versions of the drug Revlimid®. Here’s a breakdown of the developments surrounding these cases.

The share price of Dr Reddy’s Laboratories was trading lower by 0.52% as of 9:39 AM on January 23, 2025. Earlier in the day, the stock hit a fresh 1-month low of ₹1,282.95 on the NSE.

Background of the Case

The lawsuits primarily challenge the patent settlement agreements involving DRL, Celgene, and Bristol-Myers Squibb (BMS). According to the plaintiffs, these agreements allegedly violated antitrust and consumer protection laws by delaying the availability of affordable generic versions of Revlimid® until 2022 and subsequently restricting competition until 2026.

The claims against DRL mirror those against other pharmaceutical companies like Celgene, BMS, Natco, and Teva, asserting a collective effort to limit competition.

Court Proceedings So Far

1. June 2024 Ruling:
   The court dismissed key claims from similar lawsuits against other defendants, including challenges to the patent settlement agreements. Plaintiffs were allowed to amend their complaints.
2. August 2024 Amendments:
   Plaintiffs filed amended complaints, some of which added DRL as a defendant for the first time.
3. October 2024 Motions to Dismiss:
   DRL and other defendants filed motions to dismiss the amended complaints. These motions remain pending, and discovery has been stayed.
4. December 2024 Standalone Actions:
   Several plaintiffs filed additional complaints under sealed cover, targeting DRL, Natco, Teva, and AbbVie. DRL has requested permission to file motions to dismiss these standalone cases, citing reasons similar to the earlier filings.

Current Status

As of January 2025, the legal proceedings are ongoing. The court is reviewing motions to dismiss filed by DRL and other defendants in both the primary and standalone actions. No discovery has been initiated, leaving the outcome uncertain at this stage.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.